Theramex Announces an Agreement with Enzene Biosciences Limited for the Development and Commercialisation of Tocilizumab, a Biosimilar for the Treatment of Rheumatoid Arthritis
23.12.2021 17:06:00 EET | Business Wire | Press release
Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has entered into an agreement with Enzene Biosciences Limited to develop, register and commercialise a biosimilar drug of Roche’s reference medicine RoActemra® (Tocilizumab). Tocilizumab, in combination with Methotrexate (MTX), is indicated for the treatment of rheumatoid arthritis. It is planned to be commercialised from 2026 in Europe, the UK, Switzerland, and Australia.
Theramex’s Tocilizumab product will be available in parenteral vials, subcutaneous prefilled syringes and autoinjectors. The reference product RoActemra® is indicated for the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with methotrexate; moderate to severe RA adult patients who have not responded well/intolerant to DMARDs or Anti-TNFs; active systemic juvenile idiopathic arthritis in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids; juvenile idiopathic polyarthritis in patients 2 years of age and older unresponsive to MTX; treatment of Giant Cell Arteritis in adults; and chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.
Rheumatoid arthritis is a chronic condition that causes pain, swelling and stiffness in the joints. The condition usually affects the hands, feet and wrists. There may be periods where symptoms become worse, known as flares. A flare can be difficult to predict, but with treatment it's possible to decrease the number of flares and minimise or prevent long-term damage to the joints. Some people with rheumatoid arthritis also experience problems in other parts of the body, or more general symptoms such as tiredness and weight loss1.
“Rheumatoid arthritis affects more women than men, so the addition of this biosimilar drug to our existing Rheumatology portfolio continues our strategic determination to improve access and affordability of important treatments for women. We are excited to expand our focus in Rheumatology to now include rheumatoid arthritis to help even more patients with bone diseases and joint pain”, said Theramex CEO Robert Stewart .
Dr. Himanshu Gadgil, Enzene's Whole Time Director said, "The development of Enzene’s Tocilizumab, through our innovative efforts in the manufacturing of monoclonal antibodies, marks another highlight in a series of endeavours driven by our mission to provide affordable and expanded access to crucial medicines. Our partnership with Theramex bolsters our mission to bring affordable healthcare to patients across the world”.
About Theramex
Theramex is a leading global speciality pharmaceutical company dedicated to women and their health. We support women at every stage of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis. Our commitment is to listen to and understand our patients, serve their needs and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through every stage of life.
About Enzene Biosciences Ltd.
Enzene is an innovation-driven biotech company, a subsidiary of Alkem Laboratories Ltd. (One of the top five pharmaceutical companies in India*) located in Pune, India. Enzene's focus lies in producing biosimilars, novel biologics, synthetic peptides and phytopharmaceuticals. Enzene also offers a range of biologics CDMO and CMO services.
(*as per the latest IQVIA data of MAT July 2021)
For more information on Enzene Biosciences Ltd., please visit www.enzene.com
For more information on Alkem Laboratories Ltd., please visit www.alkemlabs.com
1 https://www.nhs.uk/conditions/rheumatoid-arthritis/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211223005258/en/
Contact information
Theramex
Jesús López | Associate Director, Communication & Digital | Jesus.Lopez@Theramex.com
Enzene Biosciences Ltd.
For media enquiries,
Dr. Tarun Chawla
Head - Business Development & Business Operations
Enzene Biosciences Ltd.
For any further enquiries, please reach out to: bd@enzene.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aidoptation Receives Approval for First Fully Autonomous Driving Tests on Highways in the European Union9.7.2026 09:32:00 EEST | Press release
Aidoptation BV, the autonomous vehicle technology company headquartered at DronePort in Sint-Truiden, has received official approval from the Federal Public Service Mobility (FOD) and Transport and the Flemish Agency for Roads and Traffic (AWV) to conduct fully autonomous driving tests on public highways. The permit covers 100 km on the E313 and E314 highways in the province of Limburg, and marks the first time a Level 4 fully autonomous driving system will be tested at highway speeds on public roads in the European Union. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708112110/en/ Our car driving on the highway (in manual mode). Within the global automotive industry, Level 4 is defined as autonomous driving capable of performing all driving tasks and monitoring the environment without any human intervention. This level of autonomy is distinct from the Advanced Driver Assistance Systems (ADAS) that have been tested by se
FIFA World Cup™ Fans Embrace Referee View as Lenovo AI Brings Viewers Closer to the Pitch9.7.2026 07:00:00 EEST | Press release
New international research from Lenovo reveals that technological advancements are fundamentally changing how fans experience the FIFA World Cup 2026™, making viewers feel closer to the action than ever before. According to a survey of football fans across Australia, Canada, India, U.K., U.S., 87% say technology is improving their viewing experience, and 84% report the close-to-action camera perspectives help them feel like they're right there on the pitch. Accelerating this unprecedented view of the game is Referee View, powered by Lenovo AI that gives viewers a first-person look at the match from the referee’s point of view. The research further found: Over three-quarters (76%) of FIFA World Cup™ viewers have seen or heard about Referee View, and 91% say the close-to-action perspective is appealing. 88% say that smooth, stable footage is an important part of viewing sports footage, and nearly all fans (98%) say clear picture quality has been important when watching this FIFA World Cu
Empire State Building Observation Deck Launches Exclusive Soccer Jersey Ticket Offer for Sports Fans in July9.7.2026 01:37:00 EEST | Press release
The Empire State Building Observation Deck (ESBOD) today announced a new, exclusive ticket offer for soccer fans who don their favorite team’s duds at the “World’s Most Famous Building” in anticipation of the tournament final. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708711923/en/ Empire State Building Observation Deck Launches Exclusive Soccer Jersey Ticket Offer for Sports Fans in July Guests who plan to wear their soccer jersey to the Empire State Building Observation Deck can purchase tickets online for 15 percent off to enjoy the immersive museum experience and New York City’s best views from the 86th and 102nd Floor Observation Decks. The limited-time offer is available only to guests who wear their soccer jersey on the day of their visit from now through July 31. “Whether they rep their favorite country’s jersey or the shirt from their hometown heroes, guests can celebrate their teams with prime views of the
New Esri Press Book Shows That GIS Can Transform the Entire Campus, Starting at the Classroom9.7.2026 00:33:00 EEST | Press release
Esri has released The Spatial Edge: The Strategic Advantage of GIS Skills Across Higher Education, a practical and accessible guide that demonstrates how geographic information system (GIS) technology can unify campuses academically and operationally. While GIS is often associated with disciplines such as geography, planning, and environmental studies, The Spatial Edge expands that view through real-world case examples. The book shows how spatial thinking can connect departments; strengthen decision-making; and help institutions address complex challenges across teaching, research, and campus operations. Designed for administrators, educators, and campus leaders, the guide highlights GIS being used across higher education to: Enhance teaching and student engagement Advance interdisciplinary research Improve campus planning and operations Strengthen community partnerships Prepare graduates with in-demand geospatial skills From the classroom to facilities management, The Spatial Edge ill
Jefferies Financial Group Inc. Announces Pricing of €850,000,000 4.500% Senior Notes Due 20338.7.2026 23:16:00 EEST | Press release
Jefferies Financial Group Inc. (NYSE: JEF) (“JFG”, “we” or “our”) today announced the pricing of its public offering of €850,000,000 aggregate principal amount of 4.500% Senior Notes due 2033 (the “Notes”) with an effective yield of 4.544%, maturing, July 15, 2033. The offering is expected to settle on July 15, 2026, subject to the satisfaction of customary closing conditions. Application is expected to be made for the Notes to be admitted to the Official List of the Irish Stock Exchange plc, trading as Euronext Dublin, and admitted to trading on the Global Exchange Market of Euronext Dublin; any listing is subject to approval by Euronext Dublin. JFG intends to use the net proceeds of the offering for general corporate purposes. Jefferies International Limited served as sole global co-ordinator and joint active book-runner for the offering of the Notes, Banco Santander, S.A., Citigroup Global Markets Limited, Natixis, SMBC Bank International plc and Société Générale served as joint act
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom